These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
460 related articles for article (PubMed ID: 21923613)
1. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Czernik A; Toosi S; Bystryn JC; Grando SA Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613 [TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865 [TBL] [Abstract][Full Text] [Related]
3. A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. Jolles S Clin Exp Dermatol; 2001 Mar; 26(2):127-31. PubMed ID: 11298100 [TBL] [Abstract][Full Text] [Related]
4. A systematic review on efficacy, safety and treatment durability of intravenous immunoglobulin in autoimmune bullous dermatoses: Special focus on indication and combination therapy. Kianfar N; Dasdar S; Daneshpazhooh M; Aryanian Z; Goodarzi A Exp Dermatol; 2023 Jul; 32(7):934-944. PubMed ID: 37150538 [TBL] [Abstract][Full Text] [Related]
5. The use of intravenous immunoglobulin in autoimmune bullous diseases. Chee SN; Murrell DF Immunol Allergy Clin North Am; 2012 May; 32(2):323-30, viii. PubMed ID: 22560145 [TBL] [Abstract][Full Text] [Related]
14. Current treatment of autoimmune blistering diseases. Kasperkiewicz M; Schmidt E Curr Drug Discov Technol; 2009 Dec; 6(4):270-80. PubMed ID: 20025595 [TBL] [Abstract][Full Text] [Related]
15. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Jolles S Clin Exp Immunol; 2002 Sep; 129(3):385-9. PubMed ID: 12197877 [No Abstract] [Full Text] [Related]